GRI:NSD-GRI Bio Inc. (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.749

Change

+0.02 (+2.60)%

Market Cap

N/A

Volume

0.18M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-14 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

-1.71 (-0.41%)

USD 104.84B
REGN Regeneron Pharmaceuticals Inc

-26.03 (-3.63%)

USD 78.92B
ARGX argenx NV ADR

-4.80 (-0.72%)

USD 39.62B
ALNY Alnylam Pharmaceuticals Inc

-17.76 (-6.88%)

USD 30.22B
MRNA Moderna Inc

-0.69 (-1.96%)

USD 18.29B
UTHR United Therapeutics Corporatio..

+1.82 (+0.50%)

USD 15.91B
RPRX Royalty Pharma Plc

+0.04 (+0.13%)

USD 15.05B
SMMT Summit Therapeutics PLC

-1.53 (-8.39%)

USD 13.43B
INCY Incyte Corporation

-0.44 (-0.61%)

USD 13.41B
BMRN Biomarin Pharmaceutical Inc

-3.18 (-4.75%)

USD 12.74B

ETFs Containing GRI

UKPH:XETRA iShares UK Property UCITS.. 3.23 % 0.00 %

+0.02 (+0.61%)

N/A
IUKP:SW iShares UK Property UCITS.. 3.18 % 0.00 %

+0.01 (+0.61%)

USD 0.57B
IUKP:LSE iShares UK Property UCITS 0.00 % 0.00 %

+2.00 (+0.61%)

USD 0.57B
UKRE:LSE iShares MSCI Target UK Re.. 0.00 % 0.00 %

+0.65 (+0.61%)

USD 0.12B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -9.58% 35% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.58% 35% F 17% F
Trailing 12 Months  
Capital Gain -97.17% 3% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -97.17% 3% F 1% F
Trailing 5 Years  
Capital Gain -100.00% N/A F N/A F
Dividend Return N/A N/A N/A N/A N/A
Total Return -100.00% N/A F N/A F
Average Annual (5 Year Horizon)  
Capital Gain -35.93% 8% B- 4% F
Dividend Return -35.93% 8% B- 4% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 46.84% 66% D+ 41% F
Risk Adjusted Return -76.71% 13% F 8% B-
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector